

TheraVet announces the commercial launch of the most comprehensive line of bone substitutes in the veterinary market

- ▼ Commercial launch of BIOCERA-VET® Bone Surgery Ready-to-Use, BIOCERA-VET® Granules, BIOCERA-VET® Smartgraft and BIOCERA-VET® Osteosarcoma Ready-To-Use in Belgium, France, Netherlands, United Kingdom and Ireland
- ▼ Commercial launch of the BIOCERA-VET line also in Spain
- ▼ Brand-new webshop now operational

Gosselies (Wallonia, Belgium), June 2nd, 2022 - 07.30am CEST - TheraVet (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces today **the commercial launch of its new line of bone substitutes added over the past few months**. BIOCERA-VET® Bone Surgery Ready-to-Use, BIOCERA-VET® Granules, BIOCERA-VET® Smartgraft and BIOCERA-VET® Osteosarcoma Ready-To-Use will be available for orthopedics surgeons in Belgium, France, Netherlands, United Kingdom and Ireland; as well as in Spain.

By bringing this product line on the market, TheraVet now offers unique, innovative and exclusive bone substitutes to the veterinary surgeons. BIOCERA-VET® Bone Surgery and Osteosarcoma Ready-to-Use and BIOCERA-VET® Smartgraft are the first of their kind in veterinary medicine : they provide novel, efficient and time-saving ways of bone grafting and offer cost-effective alternatives to allograft and to autograft, the standard surgical procedure.

Distribution will be ensured by wholesalers and distributors in Belgium ([Covetrus](#)), France ([Centravet](#)), United-Kingdom & Ireland ([Veterinary Instrumentation](#)) and in Spain¹ ([Nuzoa](#)) as well as through our brand new webshop www.bioceravet.com.

Enrico Bastianelli, Chief Executive Officer of TheraVet, comments: *“We are very happy to announce the launch of these products only few months after adding them to our portfolio, showing the important efforts of the teams to reach this objective. TheraVet has now the most comprehensive and unique line of bone substitutes on the veterinary market”.*

About TheraVet SA

TheraVet is a veterinary biotechnology company specialising in osteoarticular treatments for companion animals. The Company develops targeted, safe and effective treatments to improve the quality of life of pets suffering from joint and bone diseases. For pet owners, the health of their pets is a major concern and TheraVet’s mission is to address the need for innovative and curative treatments. TheraVet works closely with international opinion leaders in order to provide a more effective response to ever-growing needs in the field of veterinary medicine. TheraVet is listed on Euronext Growth® Paris and Brussels, has its head office in Belgium (Gosselies) with a US subsidiary in Texas.

For more information, visit the TheraVet [website](#) or follow us on [LinkedIn](#) / [Facebook](#) / [Twitter](#)

¹ As from September 2022 based on the recently signed distribution agreement

About BIOCERA-VET

In close collaboration with an international scientific board, THERAVET® has developed a new line of calcium-phosphate and biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full range of innovative, easy-to-use, efficient & cost-effective bone substitutes indicated in bone surgeries where a bone graft is required and as a palliative alternative in the management of canine osteosarcoma. Based on extremely promising clinical results, this line offers the possibility of a better, more convenient and more efficient orthopedic surgery.

BIOCERA-VET® is declined in different lines:

- BIOCERA-VET® BONE SURGERY RTU, ready-to-use highly injectable self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone graft
- BIOCERA-VET® GRANULES, an affordable biocompatible calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable calcium-phosphate bone substitute for cementoplasty

For more information, visit [BIOCERA-VET](#) website.

Contacts

TheraVet

Chief Operating Officer
Sabrina Ena

investors@thera.vet

Tel: +32 (0) 71 96 00 43

Chief Corporate Officer

Julie Winand

investors@thera.vet

NewCap

Investor Relations and
Financial Communications
Théo Martin / Olivier Bricaud

theravet@newcap.eu

Tel: +33 (0)1 44 71 94 94

Press Relations

Arthur Rouillé / Ambre Delval

theravet@newcap.eu

Tel: +33 (0)1 44 71 00 15

NewCap Belgique

Press Relations

Laure-Eve Monfort

lemonfort@newcap.fr

Tél. : + 32 (0) 489 57 76 52